Aliuska Morales Helguera

Aliuska Morales Helguera

Auto-generated profile, based on publicly available information

Aliuska Morales Helguera

Center of Chemical Bioactives, University of Las Villas, Santa Clara 54838, Cuba

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
AHAliuska Morales Helguera
Aliuska Morales Helguera
RCRobert D. Combes
Robert D. Combes
MGMaykel Perez Gonzalez
Maykel Perez Gonzalez
Maria Natalia Dias Soeiro CordeiroMaria Natalia Dias Soeiro Cordeiro
Maria Natalia Dias Soeiro Cordeiro
In order to minimize expensive drug failures, is essential to determine potential activity, toxicity and ADME problems as early as possible. In view of the large libraries of compounds now being handled by combinatorial chemistry and high-throughput screening, identification of potential drug is advisable even before synthesis using computational techniques such as QSAR modeling. A great number of in silico approaches to activity/toxicity prediction have been described in the literature, using molecular 0D, 1D, 2D and 3D descriptors. Also these descriptors have been implemented in available computational tools such as DRAGON, SYBYL and CODESSA for it easy use. However, many of them only have been used to explain a few prediction problems. This review attempts to summarize present knowledge related to the computational biological activity prediction based in 2D molecular descriptors implemented in the DRAGON software. These applications rely on new computational techniques such as virtual combinatorial synthesis, virtual computational screening or inverse. Several topological molecular descriptors applications are described, ranging from simple topological indices to topological indices derived from matrices weighted with atomic and bond properties. Their advantages, limitations and its possibilities in drug design are also discussed.

1 September 2010 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
MMMarisa Marques
Marisa Marques
SBSpencer A. Brown
Spencer A. Brown
IOIsabel Oliveira
Isabel Oliveira
Maria Natalia Dias Soeiro CordeiroMaria Natalia Dias Soeiro Cordeiro
Maria Natalia Dias Soeiro Cordeiro
AMAliuska Morales-Helguera
Aliuska Morales-Helguera
José Manuel AmaranteJosé Manuel Amarante
José Manuel Amarante
Silicone gel breast implants are associated with long-term adverse events, including capsular contracture, with reported incidence rates as high as 50 percent. However, it is not clear how long the follow-up period should be and whether there is any association with estrogen or menopausal status. In addition, the placement of Baker grade II subjects in the majority of reports has been in data sets of controls instead of capsular contracture. A retrospective medical study (1998 to 2004) was performed in women (n = 157) who received textured silicone breast implants for aesthetic or reconstructive procedures at the Hospital of S. João (Portugal). Medical data were collected that included the following: patient demographics, history, lifestyle factors, surgical procedures, and postoperative complications. Statistical analyses included Pearson chi-square testing, logistic regression modeling, and chi-squared automatic interaction detection (CHAID) methods. The reconstructive cohort had a great incidence of capsular contracture compared with the cosmetic cohort. If one considered no capsular contracture versus capsular contracture, the follow-up period should be longer than 42 months. However, if considering no capsular contracture and grade II subjects versus grade III or IV subjects, a longer follow-up period of 64 months was determined. There was no association between capsular contracture and menopause/estrogen status. Increased frequencies of capsular contracture were recorded in breast reconstruction that were not attributable to estrogen or menopausal status. On the basis of these results, the authors propose a follow-up period longer than 42 months and the inclusion of Baker grade II subjects.

1 May 2005 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MFMichael Fernandez
Michael Fernandez
JCJulio Caballero
Julio Caballero
AHAliuska Morales Helguera
Aliuska Morales Helguera
ECEduardo A. Castro
Eduardo A. Castro
MGMaykel Pérez González
Maykel Pérez González

1 April 2006 in Chemometrics and Intelligent Laboratory Systems
Verified
Journal Article
Closed access
AMAliuska Helguera Morales
Aliuska Helguera Morales
PDPablo R. Duchowicz
Pablo R. Duchowicz
Miguel Angel Cabrera-PerezMiguel Angel Cabrera-Perez
Miguel Angel Cabrera-Perez
ECEduardo A. Castro
Eduardo A. Castro
Maria Natalia Dias Soeiro CordeiroMaria Natalia Dias Soeiro Cordeiro
Maria Natalia Dias Soeiro Cordeiro
MGMaykel Pérez González
Maykel Pérez González

1 January 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AHAliuska Morales Helguera
Aliuska Morales Helguera
APAlfonso Pérez-Garrido
Alfonso Pérez-Garrido
Alexandra GasparAlexandra Gaspar
Alexandra Gaspar
JRJoana Reis
Joana Reis
Fernando FaginFernando Fagin
Fernando Fagin
Fernanda BorgesFernanda Borges
Fernanda Borges

17 September 2011 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
APAlfonso Pérez-Garrido
Alfonso Pérez-Garrido
AHAliuska Morales Helguera
Aliuska Morales Helguera
Fernanda BorgesFernanda Borges
Fernanda Borges
Maria Natalia Dias Soeiro CordeiroMaria Natalia Dias Soeiro Cordeiro
Maria Natalia Dias Soeiro Cordeiro
VIRGINIA RIVERO BUCETAVIRGINIA RIVERO BUCETA
VIRGINIA RIVERO BUCETA
AEAmalio Garrido Escudero
Amalio Garrido Escudero